Zurcher Kantonalbank Zurich Cantonalbank raised its position in Thermo Fisher Scientific Inc (NYSE:TMO) by 13.3% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 235,846 shares of the medical research company’s stock after purchasing an additional 27,647 shares during the quarter. Zurcher Kantonalbank Zurich Cantonalbank owned 0.06% of Thermo Fisher Scientific worth $41,148,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of the business. BlackRock Inc. raised its position in shares of Thermo Fisher Scientific by 2,692.1% during the first quarter. BlackRock Inc. now owns 22,988,885 shares of the medical research company’s stock worth $3,531,095,000 after acquiring an additional 22,165,530 shares during the last quarter. Harbour Capital Advisors LLC raised its position in shares of Thermo Fisher Scientific by 18,197.5% during the second quarter. Harbour Capital Advisors LLC now owns 1,201,051 shares of the medical research company’s stock worth $6,884,000 after acquiring an additional 1,194,487 shares during the last quarter. Veritas Asset Management LLP bought a new position in shares of Thermo Fisher Scientific during the first quarter worth about $175,795,000. Vanguard Group Inc. raised its position in shares of Thermo Fisher Scientific by 2.7% during the first quarter. Vanguard Group Inc. now owns 25,971,301 shares of the medical research company’s stock worth $3,989,193,000 after acquiring an additional 695,079 shares during the last quarter. Finally, Renaissance Technologies LLC raised its position in shares of Thermo Fisher Scientific by 68.8% during the first quarter. Renaissance Technologies LLC now owns 1,373,044 shares of the medical research company’s stock worth $210,900,000 after acquiring an additional 559,400 shares during the last quarter. Hedge funds and other institutional investors own 83.36% of the company’s stock.

A number of equities analysts have recently issued reports on TMO shares. Zacks Investment Research upgraded Thermo Fisher Scientific from a “hold” rating to a “buy” rating and set a $212.00 price objective for the company in a research report on Thursday, September 21st. Bank of America Corporation restated a “buy” rating and set a $210.00 price objective (up from $200.00) on shares of Thermo Fisher Scientific in a research report on Friday, July 21st. Cowen and Company restated an “outperform” rating and set a $220.00 price objective (up from $200.00) on shares of Thermo Fisher Scientific in a research report on Sunday, September 10th. BidaskClub downgraded Thermo Fisher Scientific from a “strong-buy” rating to a “buy” rating in a research report on Monday, July 31st. Finally, Barclays PLC restated an “overweight” rating and set a $215.00 price objective (up from $200.00) on shares of Thermo Fisher Scientific in a research report on Monday, September 25th. One investment analyst has rated the stock with a hold rating and sixteen have issued a buy rating to the company. Thermo Fisher Scientific has an average rating of “Buy” and an average target price of $202.21.

ILLEGAL ACTIVITY WARNING: “Zurcher Kantonalbank Zurich Cantonalbank Boosts Holdings in Thermo Fisher Scientific Inc (TMO)” was originally posted by Watch List News and is the property of of Watch List News. If you are reading this article on another publication, it was illegally copied and republished in violation of United States & international trademark and copyright law. The legal version of this article can be read at https://www.watchlistnews.com/zurcher-kantonalbank-zurich-cantonalbank-boosts-holdings-in-thermo-fisher-scientific-inc-tmo/1609200.html.

Shares of Thermo Fisher Scientific Inc (NYSE:TMO) opened at 193.51 on Thursday. The company has a market capitalization of $75.49 billion, a P/E ratio of 33.71 and a beta of 1.05. Thermo Fisher Scientific Inc has a one year low of $139.07 and a one year high of $194.30. The firm has a 50-day moving average price of $185.59 and a 200-day moving average price of $173.48.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings results on Wednesday, July 26th. The medical research company reported $2.30 EPS for the quarter, beating analysts’ consensus estimates of $2.27 by $0.03. The business had revenue of $5 billion during the quarter, compared to analyst estimates of $4.92 billion. Thermo Fisher Scientific had a return on equity of 15.97% and a net margin of 11.80%. Thermo Fisher Scientific’s quarterly revenue was up 10.2% compared to the same quarter last year. During the same quarter in the prior year, the company posted $2.03 EPS. Equities analysts forecast that Thermo Fisher Scientific Inc will post $9.35 earnings per share for the current year.

The firm also recently declared a quarterly dividend, which will be paid on Monday, October 16th. Shareholders of record on Friday, September 15th will be given a dividend of $0.15 per share. This represents a $0.60 dividend on an annualized basis and a yield of 0.31%. The ex-dividend date is Thursday, September 14th. Thermo Fisher Scientific’s payout ratio is 10.45%.

In other Thermo Fisher Scientific news, VP Peter E. Hornstra sold 3,894 shares of the company’s stock in a transaction that occurred on Tuesday, September 5th. The stock was sold at an average price of $185.18, for a total transaction of $721,090.92. Following the completion of the transaction, the vice president now owns 19,751 shares of the company’s stock, valued at approximately $3,657,490.18. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director C Martin Harris sold 360 shares of the company’s stock in a transaction that occurred on Wednesday, August 30th. The shares were sold at an average price of $180.97, for a total value of $65,149.20. Following the transaction, the director now directly owns 5,312 shares of the company’s stock, valued at approximately $961,312.64. The disclosure for this sale can be found here. Insiders have sold a total of 52,738 shares of company stock valued at $9,302,112 in the last ninety days. 0.49% of the stock is currently owned by corporate insiders.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.